Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 3, 2011, Pages 302-305

  Song, Y ^a   Zhong, S X ^a   Yao, L ^a   Cai, Q ^a   Zhou, J F ^a   Liu, Y Y ^a   Huo, S S ^a   Li, S S ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

itraconazole; pulse; Sporothrix schenckii; sporotrichosis

Indexed keywords

ITRACONAZOLE;

ADULT; ARTICLE; CHEST TIGHTNESS; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; FEMALE; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SPOROTRICHOSIS; TREATMENT OUTCOME;

EID: 79751523430     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03785.x     Document Type: Article

References (25)

1. Xue SL, Li L,. Oral potassium iodide for the treatment of sporotrichosis. Mycopathologia 2009; 167: 355-356.
2. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 1993; 95: 279-285. (Pubitemid 23270285)
3. Restrepo A, Robledo J, Gõmez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413-417. (Pubitemid 16132910)
4. Conti Díaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153-156.
5. Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 1255-1265. (Pubitemid 351411897)
6. Ungpakorn R, Reangchainam S,. Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis. Clin Exp Dermatol 2006; 31: 245-247.
7. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-268. (Pubitemid 18061192)
8. Bonifaz A, Fierro L, Saúl A, Ponce RM,. Cutaneous sporotrichosis. Intermittent treatment (pulses) with itraconazole. Eur J Dermatol 2008; 18: 61-64. (Pubitemid 351158174)
9. Galhardo MC, De Oliveira RM, Valle AC, et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2008; 46: 141-151. (Pubitemid 351372333)
10. Meinerz AR, Nascente Pda S, Schuch LF, et al. In vitro susceptibility of isolates of Sporothrix schenckii to terbinafine and itraconazole. Rev Soc Bras Med Trop 2007; 40: 60-62. (Pubitemid 46748599)
11. Gutierrez-Galhardo MC, Zancopé-Oliveira RM, Monzõn A, et al. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses 2010; 53: 227-231.
12. Kohler LM, Monteiro PC, Hahn RC, Hamdan JS,. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol 2004; 42: 4319-4320. (Pubitemid 39296166)
13. Kikuchi I, Morimoto K, Kawana S, Tanuma H,. Usefulness of itraconazole for sporotrichosis in Japan: study of three cases and literature comparison of therapeutic effects before and after release on the market. Eur J Dermatol 2006; 16: 42-47. (Pubitemid 43219404)
14. Kauffman CA,. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981-985.
15. Mahajan VK, Sharma NL, Sharma RC, et al. Cutaneous sporotrichosis in Himachal Pradesh, India. Mycoses 2005; 48: 25-31. (Pubitemid 40255397)
16. Yan YL,. Thirteen cases of Sporotrichosis treated by itraconazole. Chin J Dermatol 1996; 29: 229-300. [In Chinese]
17. Marimon R, Gené J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol 2006; 44: 3251-3256. (Pubitemid 44413760)
18. Marimon R, Cano J, Gené J, et al. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 2007; 45: 3198-3206. (Pubitemid 47585640)
19. Sandhu K, Gupta S,. Potassium iodide remains the most effective therapy for cutaneous sporotrichosis. J Dermatolog Treat 2003; 14: 200-202. (Pubitemid 37474528)
20. Piérard GE, Arrese JE, Piérard-Franchimont C,. Itraconazole. Expert Opin Pharmacother. 2000; 1: 287-304.
21. Negroni R, Arechavala AI,. Itraconazole: pharmacokinetics and indications. Arch Med Res 1993; 24: 387-393. (Pubitemid 24030325)
22. Tuccori M, Bresci F, Guidi B, et al. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother 2008; 42: 1112-1117.
23. Srebrnik A, Levtov S, Ben-Ami R, Brenner S,. Liver failure and transplantation after itraconazole treatment for toenail onychomycosis. J Eur Acad Dermatol Venereol 2005; 19: 205-207. (Pubitemid 40450426)
24. Gupta A, Lambert J, Revuz J, Shear N,. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol 2001; 11: 6-10. (Pubitemid 32150371)
25. Chang CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007; 120: 791-798.